CVRx Will Present Barostim Data in Phoenix
Barostim clinical findings will be featured at the Heart Failure Society of America Annual Scientific Meeting.
Updated on Sept. 29, 2026 in Heart Disease
Live Poll
Do you believe new medical device innovations are effectively improving heart failure treatment outcomes?
CVRx will present new data on the Barostim implantable heart failure device at the Heart Failure Society of America Annual Scientific Meeting 2026. The conference is scheduled to occur in Phoenix from October 9 to October 12, 2026.
Why it matters
The presentations aim to provide further clinical evidence for Barostim, an FDA-approved device designed to alleviate heart failure symptoms by balancing the autonomic nervous system. These findings could influence treatment standards for patients seeking to manage the condition through neuromodulation.
The conference program includes five podium discussions, two sponsored symposia, and one ePoster hub session featuring the BENEFIT-HF clinical trial. Researchers will present four separate data sets, including findings from the REBALANCE Registry.
The players
CVRx
Headquartered in Minneapolis, this medical technology company specializes in developing devices that stimulate the nervous system to treat cardiovascular conditions.
Heart Failure Society of America
This professional organization is dedicated to the advancement of heart failure research and the improvement of patient care through annual scientific meetings.
The details
Barostim treats heart failure by delivering electrical pulses to baroreceptors located in the carotid artery. By stimulating these receptors, the device restores balance to the autonomic nervous system to help reduce patient symptoms.
Timeline
October 9, 2026: The meeting begins with device discussion forums and posters.
October 10, 2026: A poster presentation regarding device interaction is scheduled.
October 11, 2026: Experts will conduct a plenary session and rapid-fire research presentations.
October 12, 2026: The final device discussion session of the conference will take place.
The Big Picture
The emergence of data regarding the FDA-approved Barostim implantable device follows the trend of increasing interest in neuromodulation for chronic conditions. These clinical updates are positioned to expand the established therapeutic applications of this specific technology.
Patients may see shifts in their treatment protocols as new real-world evidence from registries and clinical trials enters the medical community. These findings help doctors better understand the long-term role of neuromodulation therapy in managing chronic heart failure.
The takeaway
Clinicians and patients benefit from ongoing research that validates how neuro-stimulation devices can alter the trajectory of heart failure management. Reviewing updated clinical registry data can provide residents and medical professionals in Phoenix with a clearer understanding of current device-based treatment options.
Further reading
For more information on the management of chronic cardiac conditions, visit our Heart Disease section.
More information
To learn more about Barostim, visit the learn more about Barostim page.
Live Poll
Do you believe new medical device innovations are effectively improving heart failure treatment outcomes?
